EUVIMEDEUVIMED entdecken
Crossref

Pyrazolopyrimidinone Based Selective Inhibitors of PDE5 for the Treatment of Erectile Dysfunction

Abhinandan D Hudwekar, Pankul Kotwal, Mohd Ishaq Dar, Shilpi Balgotra, Ashish Dogra, Jaspreet Kour, Santosh S Chobe, Utpal Nandi, Sajad Hussain Syed, Sanghapal D Sawant

Chemistry & Biodiversity · 2023

DOI: 10.1002/cbdv.202200707 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Chemistry & Biodiversity, 2023. Verfasst von Abhinandan D Hudwekar und 9 weiteren Autor:innen. Beteiligte Einrichtung: Natural Products and Medicinal Chemistry Division, CSIR-Indian Institute of Integrative Medicine, Canal Road, Jammu, 180001, UT of J&K, India. Hauptthemen laut MEDLINE: Erectile Dysfunction, Phosphodiesterase 5 Inhibitors. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 43 Literaturangaben. Gefördert von: HCP, DST-SERB.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Continuing research with our earlier finding of sildenafil based analogs in the search of new inhibitors of PDE5 for erectile dysfunction suggested that there is a scope of modifications at N‐methylpiperazine ring with hydrophobic region followed by hydrogen bond donor or acceptor region. However, the leads identified earlier had some limitations like poor pharmacokinetic (PK) profile, low aqueous solubility and poor bioavailability. In this direction, a new series of sildenafil based analogs were designed, synthesized and screened for their PDE5 inhibitory activity. In this series compound 18 was found to have excellent in vitro activity with selectivity towards PDE5 isozyme, also the in vivo activity and pharmacokinetic profile was excellent. The cyp inhibition and CaCO 2 permeability was also excellent for compound 18 .

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Erectile DysfunctionPhosphodiesterase 5 InhibitorsHumansMaleCyclic Nucleotide Phosphodiesterases, Type 5Sildenafil CitrateTriiodobenzoic AcidsPyrazolesPyrimidinones

Stichwörter der Autor:innen

PDE5 inhibitorsPDE6 enzymeerectile dysfunctionpyrazolopyrimidinone scaffoldsildenafil

Substanzen

Cyclic Nucleotide Phosphodiesterases, Type 5Phosphodiesterase 5 InhibitorsSildenafil CitrateTriiodobenzoic AcidspyrazolopyrimidinonePyrazolesPyrimidinones

Autor:innen und Institutionen

  • Natural Products and Medicinal Chemistry Division, CSIR-Indian Institute of Integrative Medicine, Canal Road, Jammu, 180001, UT of J&K, India.
  • Academy of Scientific and Innovative Research, Ghaziabad, 201002, Uttar Pradesh, India.
  • Department of Biochemistry, Vanderbilt University, School of Medicine, Nashville, Tennessee, 37232-0146, United States.
  • PK-PD Tox Division, CSIR-Indian Institute of Integrative Medicine, Canal Road, Jammu, 180001, UT of J&K, India.
  • Pharmacology Division, CSIR-Indian Institute of Integrative Medicine, Sanat Nagar, Srinagar- 190005, UT of J&K, India.
  • Department of Chemistry, Central University of Jammu, Bagla Suchani, 181143, UT of J&K, India.

Förderung

  • HCP
  • DST-SERB

Zitieren

APA

Hudwekar, A. D., Kotwal, P., Dar, M. I., Balgotra, S., Dogra, A., Kour, J., Chobe, S. S., Nandi, U., Hussain Syed, S., & Sawant, S. D. (2023). Pyrazolopyrimidinone Based Selective Inhibitors of PDE5 for the Treatment of Erectile Dysfunction. Chemistry & Biodiversity. https://doi.org/10.1002/cbdv.202200707

Vancouver

Hudwekar AD, Kotwal P, Dar MI, Balgotra S, Dogra A, Kour J, et al. Pyrazolopyrimidinone Based Selective Inhibitors of PDE5 for the Treatment of Erectile Dysfunction. Chemistry & Biodiversity. 2023. doi:10.1002/cbdv.202200707

BibTeX
@article{Hudwekar2023,
  author = {Hudwekar, Abhinandan D and Kotwal, Pankul and Dar, Mohd Ishaq and Balgotra, Shilpi and Dogra, Ashish and Kour, Jaspreet and Chobe, Santosh S and Nandi, Utpal and Hussain Syed, Sajad and Sawant, Sanghapal D},
  title = {Pyrazolopyrimidinone Based Selective Inhibitors of PDE5 for the Treatment of Erectile Dysfunction},
  journal = {Chemistry & Biodiversity},
  year = {2023},
  doi = {10.1002/cbdv.202200707}
}
Kostenlos starten →